ARUP Launches First Clinical Spectral Flow MRD Assay
SALT LAKE CITY, July 20, 2026 ARUP Laboratories has introduced ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry,...
Blood Cancer
Advertisement
PharmaEssentia Wins Canadian Approval for BESREMi in Rare Blood Cancer
BURLINGTON, Mass., July 6, 2026 PharmaEssentia Corporation announced that its wholly owned Canadian subsidiary, FORUS Therapeutics Inc., has received...
FDA Approves Tregzi to Prevent Chronic GVHD in Blood Cancer
SILVER SPRING, Maryland, June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory...
FDA Approves Tregzi for Chronic GVHD Prevention in Blood Cancer
SILVER SPRING, Maryland, June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, developed by Orca...
Samsung Bioepis Relaunches BYOOVIZ with Harrow in the U.S.
INCHEON, South Korea, July 1, 2026 Samsung Bioepis has officially announced the U.S. relaunch of BYOOVIZ® (ranibizumab-nuna), the first...
Advertisements
FDA Approves Tregzi to Prevent Chronic GVHD in Blood Cancer
SILVER SPRING, Md., June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory...
Zymeworks Acquires Theravance to Expand Healthcare Portfolio
VANCOUVER, British Columbia, June 29, 2026 Zymeworks Inc. has announced a definitive agreement to acquire Theravance Biopharma, Inc. in...
Ipsen and Kartos Therapeutics Sign $1.75B Acquisition Deal
PARIS, France & REDWOOD CITY, Calif., June 29, 2026 Ipsen has announced a definitive agreement to acquire Kartos Therapeutics,...
PharmaEssentia Secures FDA Approval for BESREMi Pen in Polycythemia Vera
BURLINGTON, Mass., June 26, 2026 PharmaEssentia USA Corporation announced that the U.S. Food and Drug Administration (FDA) has approved...
IDEAYA Launches Phase 1/2 Study of IDE892 in MTAP-Deleted Cancers
SOUTH SAN FRANCISCO, Calif., June 15, 2026 IDEAYA Biosciences has announced the initiation of a Phase 1/2 clinical combination...
Advertisement
